IBDQ at weeks 6 or 8 · people with active UC
TNF‐alpha antagonists leads to higher improved IBDQ at weeks 6 or 8 compared with placebo (high certainty).
2 findings from 1 review
QoL · people with active UC
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Infliximab leads to higher improved IBDQ at week 8 compared with placebo (high certainty).
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
EQ‐5D at week 6 · people with active UC
1 finding from 1 review
Health‐related quality of life · people with active UC
Infliximab probably leads to higher improved SF‐36 PCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved SF‐36 MCS at week 8 · people with active UC
Infliximab probably leads to higher improved SF‐36 MCS at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 8 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 8 compared with placebo (moderate certainty).
1 finding from 1 review
Improved IBDQ at week 52 · people with active UC
Adalimumab probably leads to higher improved IBDQ at week 52 compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · patients with induction of remission in ulcerative colitis
Etrolizumab probably leads to lower failure to enter clinical remission at week 10 compared with placebo (moderate certainty).
2 findings from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in failure to respond at week 10 compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in failure to enter endoscopic remission at week 6 compared with placebo (moderate certainty).
2 findings from 1 review
Adverse events · patients with induction of remission in ulcerative colitis
Etrolizumab probably leads to lower adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with induction of remission in ulcerative colitis
Etrolizumab showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Remission and complete withdrawal from steroids · patients with induction of remission in ulcerative colitis
Methotrexate showed no clear difference in remission and complete withdrawal from steroids compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 6‐mercaptopurine (very low certainty).
1 finding from 1 review
Clinical remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).
1 finding from 1 review
Failure to induce clinical remission at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce clinical remission compared with placebo (high certainty).
1 finding from 1 review
Failure to induce clinical response at end of study · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower failure to induce clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Failure to induce endoscopic remission · Patients with moderately to severely active ulcerative colitis
Vedolizumab leads to lower failure to induce endoscopic remission compared with placebo (high certainty).
1 finding from 1 review